At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 521 enrolled
Drug / intervention
Etanercept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
In Brief
A Phase 3 clinical trial evaluating Etanercept and CHS-0214 for Plaque Psoriasis. Completed, enrolled 521 participants across 100 sites in 7 countries.
Detailed Summary
This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesAustralia, Canada, Germany, Israel, Poland, South Africa, United States
CollaboratorsShire
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartJun 2014
Primary CompletionJul 2015
Study CompletionMay 2016
TodayJul 2026
First PostedMay 9, 2014
Enrollment StartJun 16, 2014
Primary CompletionJul 27, 2015
Study CompletionMay 12, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.1 years ago
Interventions
Etanerceptdrug
Head-to-head comparison
CHS-0214drug